Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Schizophrenia

  Free Subscription


Articles published in J Clin Psychiatry

Retrieve available abstracts of 89 articles:
HTML format



Single Articles


    July 2021
  1. VERAART JKE, Smith-Apeldoorn SY, Spijker J, Kamphuis J, et al
    Ketamine Treatment for Depression in Patients With a History of Psychosis or Current Psychotic Symptoms: A Systematic Review.
    J Clin Psychiatry. 2021;82.
    PubMed     Abstract available


  2. BALLARD C, Aarsland D
    Relieving Caregiver Burden Through Evidence-Based Treatment for Dementia-Related Psychosis.
    J Clin Psychiatry. 2021;82.
    PubMed     Abstract available


    May 2021
  3. DUBREUCQ M, Plasse J, Gabayet F, Blanc O, et al
    Sex Differences in Recovery-Related Outcomes and Needs for Psychiatric Rehabilitation in People With Schizophrenia Spectrum Disorder.
    J Clin Psychiatry. 2021;82.
    PubMed     Abstract available


  4. SHINN AK, Carol EE
    The Importance of Context in Identifying the Recovery Needs of Women With Psychosis.
    J Clin Psychiatry. 2021;82.
    PubMed    


  5. CHEN YQ, Li XR, Zhang L, Zhu WB, et al
    Therapeutic Response Is Associated With Antipsychotic-Induced Weight Gain in Drug-Naive First-Episode Patients With Schizophrenia: An 8-Week Prospective Study.
    J Clin Psychiatry. 2021;82.
    PubMed     Abstract available


  6. HARVEY PD, Kane JM
    Addressing Patients' Unmet Needs to Improve Outcomes in Schizophrenia.
    J Clin Psychiatry. 2021;82.
    PubMed     Abstract available


    April 2021
  7. BALLARD C
    Evidence-Based Treatment and Monitoring Strategies for Dementia-Related Psychosis.
    J Clin Psychiatry. 2021;82.
    PubMed     Abstract available


    March 2021
  8. KANE JM
    Lessening the Side Effect Burden to Improve Adherence Among Individuals With Schizophrenia.
    J Clin Psychiatry. 2021;82.
    PubMed     Abstract available


  9. HARVEY PD
    Patient-Centered Treatment Strategies to Improve Outcomes in Schizophrenia.
    J Clin Psychiatry. 2021;82.
    PubMed     Abstract available


    February 2021
  10. BELL KS, Henderson DC, Wright HJ, Gogate JP, et al
    Treatment Effect With Paliperidone Palmitate Compared With Oral Antipsychotics in Black/African American Patients With Schizophrenia and a History of Criminal Justice System Involvement: A Post Hoc Analysis of the PRIDE Study.
    J Clin Psychiatry. 2021;82.
    PubMed     Abstract available


    January 2021
  11. KIM S, Kim S, Koh M, Choi G, et al
    Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration.
    J Clin Psychiatry. 2021;82.
    PubMed     Abstract available


  12. MACLAURIN SA, Mulligan C, Van Alphen MU, Freudenreich O, et al
    Optimal Long-Acting Injectable Antipsychotic Management During COVID-19.
    J Clin Psychiatry. 2021;82.
    PubMed    


    December 2020
  13. CITROME L, Walling DP, Zeni CM, Starling BR, et al
    Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia: A Phase 3, Randomized, Placebo-Controlled Study.
    J Clin Psychiatry. 2020;82.
    PubMed     Abstract available


  14. BALLARD C
    Diagnosing Dementia-Related Psychosis: Using Tools and Communicating With Patients and Caregivers.
    J Clin Psychiatry. 2020;82.
    PubMed     Abstract available


    November 2020
  15. REINSTEIN SA, Cosgrove J, Malekshahi T, Deligiannidis KM, et al
    Long-Acting Injectable Antipsychotic Use During Pregnancy: A Brief Review and Concise Guide for Clinicians.
    J Clin Psychiatry. 2020;81.
    PubMed    


  16. ROSS EL, Becker JE, Linnoila JJ, Soeteman DI, et al
    Cost-Effectiveness of Routine Screening for Autoimmune Encephalitis in Patients With First-Episode Psychosis in the United States.
    J Clin Psychiatry. 2020;82.
    PubMed     Abstract available


  17. AARSLAND D
    Impact of Dementia-Related Psychosis on Patients and Caregivers: The Treatment Imperative.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


  18. SALAGRE E, Grande I, Vieta E, Mezquida G, et al
    Predictors of Bipolar Disorder Versus Schizophrenia Diagnosis in a Multicenter First Psychotic Episode Cohort: Baseline Characterization and a 12-Month Follow-Up Analysis.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


    September 2020
  19. AARSLAND D
    Epidemiology and Pathophysiology of Dementia-Related Psychosis.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


    August 2020
  20. LAURIELLO J, Claxton A, Du Y, Weiden PJ, et al
    Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


    July 2020
  21. KUROSE S, Mimura Y, Uchida H, Takahata K, et al
    Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


    June 2020
  22. CORRELL CU, Lauriello J
    Using Long-acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


  23. HIRAKAWA H, Ishii N
    Depression as a Factor in Nonadherence in Schizophrenia.
    J Clin Psychiatry. 2020;81.
    PubMed    


  24. MORILLO-GONZALEZ J, Hernandez-Huerta D, Guillama-Henriquez A, Correa-Palacio A, et al
    Beyond the Respiratory System: A Case Report Highlighting the Impact of COVID-19 in Mental Illness and Its Physical Consequences.
    J Clin Psychiatry. 2020;81.
    PubMed    


  25. KANE JM, Correll CU
    Drs Kane and Correll Reply.
    J Clin Psychiatry. 2020;81.
    PubMed    


    May 2020
  26. WEIDEN PJ, Claxton A, Kunovac J, Walling DP, et al
    Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


  27. DEVOE DJ, Farris MS, Townes P, Addington J, et al
    Interventions and Transition in Youth at Risk of Psychosis: A Systematic Review and Meta-Analyses.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


  28. LAURIELLO J
    Patient-Centered Psychopharmacology and Psychosocial Interventions: Treatment Selection and Shared Decision-Making to Enhance Chances for Recovery.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


    April 2020
  29. GUINART D, Correll CU
    Antipsychotic Polypharmacy in Schizophrenia: Why Not?
    J Clin Psychiatry. 2020;81.
    PubMed    


  30. CORRELL CU
    Current Treatment Options and Emerging Agents for Schizophrenia.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


  31. CORRELL CU
    Using Patient-Centered Assessment in Schizophrenia Care: Defining Recovery and Discussing Concerns and Preferences.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


    March 2020
  32. LAURIELLO J
    Prevalence and Impact of Relapse in Patients With Schizophrenia.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


  33. ZHANG Y, Wang Q, Reynolds GP, Yue W, et al
    Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


  34. PATHAK S, Jiang Y, DiPetrillo L, Todtenkopf MS, et al
    Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


  35. GILDEN J, Kamperman AM, Munk-Olsen T, Hoogendijk WJG, et al
    Long-Term Outcomes of Postpartum Psychosis: A Systematic Review and Meta-Analysis.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


  36. BRUNETTE MF, Correll CU, O'Malley SS, McDonnell D, et al
    Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


  37. PUIG O, Fisher M, Loewy R, Miley K, et al
    Early- Versus Adult-Onset Schizophrenia as a Predictor of Response to Neuroscience-Informed Cognitive Training.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


  38. POTKIN SG, Kunovac J, Silverman BL, Simmons A, et al
    Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


  39. LAUGHREN TP
    A Growing Crisis in Schizophrenia Drug Development: Failing Signal Detection at North American and Other Clinical Trial Sites.
    J Clin Psychiatry. 2020;81.
    PubMed    


  40. GOPALAKRISHNAN M, Zhu H, Farchione TR, Mathis M, et al
    The Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues: An Update From the US Food and Drug Administration.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


    February 2020
  41. CITROME L, Saklad SR
    Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


  42. ANDRADE C
    Transcranial Direct Current Stimulation for Negative Symptoms of Schizophrenia: Why the Reader Must Choose a Clinically Relevant Outcome.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


    January 2020
  43. MCEVOY JP, Kremens DE
    Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia.
    J Clin Psychiatry. 2020;81.
    PubMed     Abstract available


    December 2019
  44. MCEVOY JP
    Psychosocial Implications of Tardive Dyskinesia in Patients With Mood Disorders Versus Schizophrenia.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


    November 2019
  45. ANDREA S, Papirny M, Raedler T
    Brain Imaging in Adolescents and Young Adults With First-Episode Psychosis: A Retrospective Cohort Study.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


    October 2019
  46. WANG DM, Zhang GY, Du XD, Jia QF, et al
    Sex Differences in the Prevalence and Clinical Features of Comorbid Depressive Symptoms in Never-Treated Chinese Patients With First-Episode Schizophrenia.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


    September 2019
  47. KRIVOY A, Joyce D, Tracy D, Gaughran F, et al
    Real-World Outcomes in the Management of Refractory Psychosis.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


  48. KANE JM, Correll CU
    Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


    August 2019
  49. MUSTAFA S, Joober R, Iyer S, Shah J, et al
    Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


    July 2019
  50. NIA AB, Mann CL, Spriggs S, DeFrancisco DR, et al
    The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


    April 2019
  51. CHEN MH, Pan TL, Huang KL, Hsu JW, et al
    Coaggregation of Major Psychiatric Disorders in First-Degree Relatives of Individuals With Attention-Deficit/Hyperactivity Disorder: A Nationwide Population-Based Study.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


  52. KANE JM, Schooler NR, Marcy P, Achtyes ED, et al
    Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


  53. CUI Y, Kim SW, Lee BJ, Kim JJ, et al
    Negative Schema and Rumination as Mediators of the Relationship Between Childhood Trauma and Recent Suicidal Ideation in Patients With Early Psychosis.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


    March 2019
  54. LAURIELLO J, Perkins DO
    Managing Transitions in Care and Adherence to Improve Outcomes in Schizophrenia.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


  55. FADEN J
    Treatment-Resistant Schizophrenia: A Brief Overview of Treatment Options.
    J Clin Psychiatry. 2019;80.
    PubMed    


  56. KANE JM, Agid O, Baldwin ML, Howes O, et al
    Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


    February 2019
  57. LAURIELLO J, Perkins DO
    Enhancing the Treatment of Patients With Schizophrenia Through Continuous Care.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


    January 2019
  58. GORDON JA
    NIMH Supports Evidence-Based Treatments for Schizophrenia: A Response to Torrey et al.
    J Clin Psychiatry. 2019;80.
    PubMed    


  59. TORREY EF, Yolken RH, Lamb HR
    NIMH Drug Trials for Schizophrenia.
    J Clin Psychiatry. 2019;.
    PubMed    


  60. CORRELL CU, Potkin SG, Zhong Y, Harsanyi J, et al
    Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


  61. MISDRAHI D, Tessier A, Daubigney A, Meissner WG, et al
    Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
    J Clin Psychiatry. 2019;80.
    PubMed     Abstract available


    December 2018
  62. KUMAGAI F, Suzuki T, Fleischhacker WW, Yasui-Furukori N, et al
    Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs.
    J Clin Psychiatry. 2018;80.
    PubMed     Abstract available


    September 2018
  63. ANDRADE C
    The Use of Statins for Antipsychotic Augmentation in Schizophrenia: Examination of Meta-Analyses With Flawed Methods and Conclusions.
    J Clin Psychiatry. 2018;79.
    PubMed     Abstract available


  64. GODIN O, Leboyer M, Schurhoff F, Llorca PM, et al
    Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort.
    J Clin Psychiatry. 2018;79.
    PubMed     Abstract available


    July 2018
  65. ZHANG XY, Du X, Yin G, Zhang Y, et al
    Prevalence and Clinical Correlates of and Cognitive Function at the Time of Suicide Attempts in First-Episode and Drug-Naive Patients With Schizophrenia.
    J Clin Psychiatry. 2018;79.
    PubMed     Abstract available


  66. CHENGAPPA KNR, Brar JS, Gannon JM, Schlicht PJ, et al
    Adjunctive Use of a Standardized Extract of Withania somnifera (Ashwagandha) to Treat Symptom Exacerbation in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study.
    J Clin Psychiatry. 2018;79.
    PubMed     Abstract available


    June 2018
  67. EMSLEY R, Nuamah I, Gopal S, Hough D, et al
    Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence: A Post Hoc Analysis of a Randomized Placebo-Controlled Study.
    J Clin Psychiatry. 2018;79.
    PubMed     Abstract available


    May 2018
  68. KEEFE RSE, Harvey PD, Khan A, Saoud JB, et al
    Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial.
    J Clin Psychiatry. 2018;79.
    PubMed     Abstract available


    April 2018
  69. LEE EE, Martin AS, Tu X, Palmer BW, et al
    Childhood Adversity and Schizophrenia: The Protective Role of Resilience in Mental and Physical Health and Metabolic Markers.
    J Clin Psychiatry. 2018;79.
    PubMed     Abstract available


  70. HOU CL, Chen MY, Cai MY, Chen ZL, et al
    Antipsychotic-Free Status in Community-Dwelling Patients With Schizophrenia in China: Comparisons Within and Between Rural and Urban Areas.
    J Clin Psychiatry. 2018;79.
    PubMed     Abstract available


    March 2018
  71. TAKEUCHI H, Fathi A, Thiyanavadivel S, Agid O, et al
    Can Aripiprazole Worsen Psychosis in Schizophrenia? A Meta-Analysis of Double-Blind, Randomized, Controlled Trials.
    J Clin Psychiatry. 2018;79.
    PubMed     Abstract available


    November 2017
  72. TSOUTSOULAS C, Mulsant BH, Kumar S, Ghazala Z, et al
    Anticholinergic Burden and Cognition in Older Patients With Schizophrenia.
    J Clin Psychiatry. 2017 Nov 28. doi: 10.4088/JCP.17m11523.
    PubMed     Abstract available


  73. ANDRADE C
    Memantine as an Augmentation Treatment for Schizophrenia: Limitations of Meta-Analysis for Evidence-Based Evaluation of Research.
    J Clin Psychiatry. 2017 Nov 21. doi: 10.4088/JCP.17f11998.
    PubMed     Abstract available


  74. DEAN DJ, Bryan AD, Newberry R, Gupta T, et al
    A Supervised Exercise Intervention for Youth at Risk for Psychosis: An Open-Label Pilot Study.
    J Clin Psychiatry. 2017 Nov 21. doi: 10.4088/JCP.16m11365.
    PubMed     Abstract available


  75. MEKORI-DOMACHEVSKY E, Taler M, Shoenfeld Y, Gurevich M, et al
    Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits.
    J Clin Psychiatry. 2017 Nov 14. pii: 16m11207. doi: 10.4088/JCP.16m11207.
    PubMed     Abstract available


  76. TINKELMAN A, Hill EA, Deligiannidis KM
    Management of New Onset Psychosis in the Postpartum Period.
    J Clin Psychiatry. 2017 Nov 7. pii: 17ac11880. doi: 10.4088/JCP.17ac11880.
    PubMed    


  77. DOWNS JM, Lechler S, Dean H, Sears N, et al
    The Association Between Comorbid Autism Spectrum Disorders and Antipsychotic Treatment Failure in Early-Onset Psychosis: A Historical Cohort Study Using Electronic Health Records.
    J Clin Psychiatry. 2017 Nov 7. pii: 16m11422. doi: 10.4088/JCP.16m11422.
    PubMed     Abstract available


  78. PERKINS DO
    Improving Long-Term Outcomes in Patients With Schizophrenia: What Is the Evidence for Long-Acting Injectable Antipsychotics?
    J Clin Psychiatry. 2017;78:e1431.
    PubMed     Abstract available


    September 2017
  79. MCEVOY JP, Risinger R, Mykhnyak S, Du Y, et al
    Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia.
    J Clin Psychiatry. 2017 Sep 19. pii: 17m11625. doi: 10.4088/JCP.17m11625.
    PubMed     Abstract available


  80. HAIG GM, Wang D, Zhao J, Othman AA, et al
    Efficacy and Safety of the alpha7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.
    J Clin Psychiatry. 2017 Sep 12. pii: 16m11162. doi: 10.4088/JCP.16m11162.
    PubMed     Abstract available


  81. PUIG O, Baeza I, de la Serna E, Cabrera B, et al
    Persistent Negative Symptoms in First-Episode Psychosis: Early Cognitive and Social Functioning Correlates and Differences Between Early and Adult Onset.
    J Clin Psychiatry. 2017 Sep 12. pii: 16m11122. doi: 10.4088/JCP.16m11122.
    PubMed     Abstract available


  82. SULTAN RS, Olfson M, Correll CU, Duncan EJ, et al
    Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring.
    J Clin Psychiatry. 2017;78:e933-e939.
    PubMed     Abstract available


    June 2017
  83. WEIDEN PJ, Kim E, Bermak J, Turkoz I, et al
    Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
    J Clin Psychiatry. 2017 Jun 20. pii: 16m11308. doi: 10.4088/JCP.16m11308.
    PubMed     Abstract available


    May 2017
  84. WEISER M, Levi L, Burshtein S, Hagin M, et al
    Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    J Clin Psychiatry. 2017 May 23. pii: 15m10498. doi: 10.4088/JCP.15m10498.
    PubMed     Abstract available


  85. TOSATO S, Albert U, Tomassi S, Iasevoli F, et al
    A Systematized Review of Atypical Antipsychotics in Pregnant Women: Balancing Between Risks of Untreated Illness and Risks of Drug-Related Adverse Effects.
    J Clin Psychiatry. 2017;78:e477-e489.
    PubMed     Abstract available


  86. BERNARDINI F, Attademo L, Cleary SD, Luther C, et al
    Risk Prediction Models in Psychiatry: Toward a New Frontier for the Prevention of Mental Illnesses.
    J Clin Psychiatry. 2017;78:572-583.
    PubMed     Abstract available


    April 2017
  87. HAGEN JM, Sutterland AL, Koeter MW, Lutter R, et al
    Advanced Glycation End Products in Recent-Onset Psychosis Indicate Early Onset of Cardiovascular Risk.
    J Clin Psychiatry. 2017 Apr 25. doi: 10.4088/JCP.16m10972.
    PubMed     Abstract available


    March 2017
  88. ZHENG W, Xiang YT, Yang XH, Xiang YQ, et al
    Clozapine Augmentation With Antiepileptic Drugs for Treatment-Resistant Schizophrenia: A Meta-Analysis of Randomized Controlled Trials.
    J Clin Psychiatry. 2017 Mar 28. doi: 10.4088/JCP.16r10782.
    PubMed     Abstract available


    February 2017
  89. TAKEUCHI H, Lee J, Fervaha G, Foussias G, et al
    Switching to Clozapine Using Immediate Versus Gradual Antipsychotic Discontinuation: A Pilot, Double-Blind, Randomized Controlled Trial.
    J Clin Psychiatry. 2017;78:223-228.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: